Latest Ampio Pharmaceuticals Inc. Stories
GREENWOOD VILLAGE, Colo., July 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion(TM) , Optina(TM) & Zertane(TM)), announced the significant results from their further analysis of its Optina(TM) trial on DME . (Logo:...
GREENWOOD VILLAGE, Colo., July 3, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its four lead drugs (Ampion(TM), Optina(TM), Zertane(TM)( )& Zertane-ED(TM)) licensing distribution of these drugs and developing additional new drugs, announced today that Dr. David Bar-Or, Ampio's Founder, Chief Scientific Officer and largest shareholder, and Michael Macaluso, Ampio's CEO, Chairman and Lead Investor,...
GREENWOOD VILLAGE, Colo., July 2, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) & Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it is proceeding with the development plan for a combination product to treat both premature ejaculation (PE) and erectile dysfunction (ED). The positive pre-IND meeting...
GREENWOOD VILLAGE, Colo., June 21, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today the outcome of its pre-IND meeting with the CDER Urology and Reproductive group (DRUP) division of the FDA that took place on June 20, 2012. The FDA provided all...
GREENWOOD VILLAGE, Colo., June 11, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina(TM) clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada. (Logo:...
GREENWOOD VILLAGE, Colo., May 31, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that The European Patent Office (EPO) has notified the company that it will grant a patent covering Ampio's Optina(TM)( )product. The patent will protect...
GREENWOOD VILLAGE, Colo., May 14, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of those drugs and engaged in further drug development), will hold a webcast on Wednesday, May 16, 2012, at 4:15 p.m. EDT. Management will outline the Company's 2012 progress, provide a detailed review for each of its three lead products and...
GREENWOOD VILLAGE, Colo., May 11, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)) announced completion of a pre-IND meeting with the Center for Biological Evaluation and Research (CBER) division of the FDA that took place on May 10th regarding Ampio's lead biologic, Ampion(TM) for the chronic treatment (repeat injections) of pain in osteoarthritis...
GREENWOOD VILLAGE, Colo., April 30, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of those drugs and engaged in further drug development, announced the completion of the planned analysis of the day 84 data of the Ampion(TM) in the Knee (AIK) study conducted in Australia. With the previously reported positive results 30...
GREENWOOD VILLAGE, Colo., April 27, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that it received notice of allowance of a patent from the US office of patents and trademarks for its DME drug Optina(TM). Ampio also received a notice of allowance of a...
